Bayer (FRA:BAYN) has been assigned a €77.00 ($89.53) price objective by analysts at Jefferies Financial Group in a research report issued on Thursday. The firm presently has a “neutral” rating on the healthcare company’s stock. Jefferies Financial Group’s target price points to a potential upside of 1.18% from the company’s current price.

Several other research analysts have also recently commented on the stock. Baader Bank set a €123.00 ($143.02) target price on shares of Bayer and gave the stock a “buy” rating in a research report on Thursday. Commerzbank set a €111.00 ($129.07) target price on shares of Bayer and gave the stock a “buy” rating in a research report on Thursday. Goldman Sachs Group set a €111.00 ($129.07) target price on shares of Bayer and gave the stock a “buy” rating in a research report on Thursday. UBS Group set a €122.00 ($141.86) target price on shares of Bayer and gave the stock a “buy” rating in a research report on Wednesday. Finally, Barclays set a €100.00 ($116.28) target price on shares of Bayer and gave the stock a “buy” rating in a research report on Tuesday. Seven equities research analysts have rated the stock with a hold rating and sixteen have given a buy rating to the company’s stock. The company presently has an average rating of “Buy” and a consensus price target of €98.80 ($114.88).

FRA BAYN opened at €76.10 ($88.49) on Thursday. Bayer has a 52 week low of €91.58 ($106.49) and a 52 week high of €123.82 ($143.98).

About Bayer

Bayer Aktiengesellschaft operates as a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, Crop Science, and Animal Health segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women's health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents.

Further Reading: Conference Calls

Analyst Recommendations for Bayer (FRA:BAYN)

Receive News & Ratings for Bayer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bayer and related companies with MarketBeat.com's FREE daily email newsletter.